These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 21862072)
1. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. Amin A; Partin A; Epstein JI J Urol; 2011 Oct; 186(4):1286-90. PubMed ID: 21862072 [TBL] [Abstract][Full Text] [Related]
2. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? Makarov DV; Sanderson H; Partin AW; Epstein JI J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053 [TBL] [Abstract][Full Text] [Related]
3. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
4. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
5. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
6. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis. Ellis CL; Partin AW; Han M; Epstein JI J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307 [TBL] [Abstract][Full Text] [Related]
7. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related]
8. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy. Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491 [TBL] [Abstract][Full Text] [Related]
9. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
10. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379 [TBL] [Abstract][Full Text] [Related]
11. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896 [TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
13. Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. Sved PD; Gomez P; Manoharan M; Kim SS; Soloway MS J Urol; 2004 Jul; 172(1):98-102. PubMed ID: 15201746 [TBL] [Abstract][Full Text] [Related]
14. Initial atypical diagnosis with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy. Chen YB; Pierorazio PM; Epstein JI J Urol; 2010 Nov; 184(5):1953-7. PubMed ID: 20846684 [TBL] [Abstract][Full Text] [Related]
15. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ J Urol; 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PubMed ID: 17085127 [TBL] [Abstract][Full Text] [Related]
16. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. San Francisco IF; Regan MM; Olumi AF; DeWolf WC J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206 [TBL] [Abstract][Full Text] [Related]
17. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Grober ED; Tsihlias J; Jewett MA; Sweet JM; Evans AJ; Trachtenberg J; Robinette M; Nam RK Can J Urol; 2004 Feb; 11(1):2157-62. PubMed ID: 15003158 [TBL] [Abstract][Full Text] [Related]
18. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy. Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204 [TBL] [Abstract][Full Text] [Related]
20. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]